Selective EGFR inhibitors have been recommended as first-line therapy in lung cancer patients harboring EGFR mutations [3-5], and have also shown modest effectiveness against tumors of the pancreas [6, 7] Identification that EGFR is expressed in up to 90% of certain histotypes of ovarian tumors led to investigation of this molecule as a potential prognostic biomarker as well as therapeutic target in ovarian cancer [8, 9]. This evidence concerns the gene EGFR and ovarian cancer.